PEMFEXY

Peak

pemetrexed

NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo…

Clinical Trials (5)

NCT07229339Phase 2Not Yet Recruiting

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Started Jun 2027
NCT07100080Phase 2/3Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Started Nov 2025
596 enrolled
Non-Small Cell Lung Cancer
NCT06793215Phase 3Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Started Oct 2025
600 enrolled
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
NCT06305754Phase 3Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Started Jun 2024
520 enrolled
Non-small Cell Lung Cancer (NSCLC)
NCT06097728Phase 3Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Started Nov 2023
825 enrolled
Unresectable Pleural Mesothelioma

Loss of Exclusivity

LOE Date
Feb 19, 2036
121 months away
Patent Expiry
Feb 19, 2036

Patent Records (3)

Patent #ExpiryTypeUse Code
9604990
Oct 28, 2035
Substance
11793813
Feb 19, 2036
Product
12115164
Feb 19, 2036
U-4248